Analyst: FDA Won't Pull Permit On Orexigen Therapeutics By: Benzinga via Benzinga March 06, 2015 at 14:56 PM EST Orexigen Therapeutics, Inc. (NASDAQ: OREX) sole product, the anti-obesity drug Contrave, almost certainly won't get pulled from ... Read More >> Related Stocks: RBC Bearings Inc